Fig 7.
Pair-mate analysis of patients treated with total therapy 2 (TT2) and total therapy 1 (TT1). Matching was done on cytogenetic abnormalities (CA), CRP (>8 mg/l) and creatinine (≥176.8 μmol/l), found to be the leading adverse variables in TT1. (A) Overall survival tended to be superior with TT2 versus TT1. (B) Event-free survival was superior with TT2 (both arms) versus TT1. (C) Duration of complete remission (CR) was superior with TT2 (both arms) versus TT1.